IP Library Granted Patent US 9,700,609
Granted Patent B2
US 9,700,609 · App. 14/774,461 · Granted Jul 11, 2017

Compositions for treatment and/or prevention of autoimmune disorders

Inventors: Joseph Larkin (Gainesville, FL); Mark A. Atkinson (Gainesville, FL)
Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
A61K39/02A61K35/15A61K39/0008A61K39/0208A61K39/08A61K39/09A61K2039/5154A61K2039/5158A61K2039/577A61K2039/58
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,700,609
App. No.
14/774,461
Granted
Jul 11, 2017
Kind
B2
Abstract

The invention provides compositions for treating or preventing T1D (T1D), the compositions comprising one or more antigen presenting cells (APC) that have been pulsed with one or more bacteria and/or components of the bacteria, wherein the bacteria or their components confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells. The subject invention also provides a method of treating or preventing T1D in a subject, the method comprising administering APC that have been pulsed with one or more bacteria and/or components of the bacteria and wherein the bacteria or their components confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells.

Claims (3)

1. A method of treating or preventing type 1 Diabetes (TID), the method comprising administering to a human who has been diagnosed as having diabetes, or at risk for diabetes, an antigen presenting cell (APC) contacted with a suppressor of cytokine signaling-1 (SOCS1) protein peptide or mimetic inhibitor that antagonizes the activity of SOCS1 protein, wherein said contacting confers upon the APC the ability to inhibit the generation of diabetogenic T cells.

2. The method of claim 1 , wherein the APC is a dendritic cell (DC).

3. The method of claim 1 , wherein the peptide is selected from the group consisting of SOCS1-kinase inhibitory region (SOCS1-KIR) peptide, SOCS1-KIR2A, Tyrosine Kinase Inhibitory Peptide (TKIP), SOCS1-KIR dimer, JAK2 (1001-1013), and pJAK2(1001-1013).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2016
From: LARKIN, JOSEPH; ATKINSON, MARK
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 037450/0580 →
Continuity (2)
Provisional Application 61793321 · Mar 15, 2013
Related Publication 20160022793A1 · Jan 28, 2016